The stock of Chiasma Inc (NASDAQ:CHMA) is a huge mover today! About 80,056 shares traded hands. Chiasma Inc (NASDAQ:CHMA) has declined 79.82% since April 13, 2016 and is downtrending. It has underperformed by 83.74% the S&P500.
The move comes after 9 months negative chart setup for the $52.34M company. It was reported on Nov, 15 by Barchart.com. We have $1.83 PT which if reached, will make NASDAQ:CHMA worth $6.80M less.
Chiasma Inc (NASDAQ:CHMA) Ratings Coverage
Out of 3 analysts covering Chiasma (NASDAQ:CHMA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Chiasma has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The company was initiated on Monday, August 10 by Cowen & Co. Barclays Capital initiated Chiasma Inc (NASDAQ:CHMA) rating on Monday, August 10. Barclays Capital has “Overweight” rating and $40 price target. The rating was downgraded by Barclays Capital on Monday, April 25 to “Equal-Weight”. The stock has “Market Perform” rating given by William Blair on Monday, April 18. The firm has “Outperform” rating by William Blair given on Monday, August 10.
According to Zacks Investment Research, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA.”
More important recent Chiasma Inc (NASDAQ:CHMA) news were published by: Marketwatch.com which released: “Chiasma’s stock plummets 54% premarket after FDA response letter” on June 18, 2015, also Quotes.Wsj.com published article titled: “Chiasma Inc. CHMA (US: Nasdaq)”, Prnewswire.com published: “Chiasma, Inc. Prices Initial Public Offering of Common Stock” on July 15, 2015. More interesting news about Chiasma Inc (NASDAQ:CHMA) was released by: Streetinsider.com and their article: “Chiasma, Inc. (CHMA) Names Mark J. Fitzpatrick as CEO” with publication date: September 30, 2016.
CHMA Company Profile
Chiasma, Inc., incorporated on April 12, 2001, is a biopharmaceutical company. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Firm has completed a Phase III clinical trial of its TPE platform product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.